# Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Source: https://onco.cc/trials/nct04416984/  
OnCo record `nct04416984` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ALLO-647, Fludarabine and Cyclophosphamide in chronic lymphocytic leukaemia, run by Allogene Therapeutics, active and no longer recruiting.

## Summary

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) is a phase 1/2 interventional study registered as NCT04416984 by Allogene Therapeutics, with 160 participants enrolled, started 2020-05-21 and due to reach its primary completion in 2029-02. Interventions recorded: ALLO-501A, ALLO-647, Fludarabine and Cyclophosphamide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04416984
- Phase: 1/2
- Setting: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
- Sponsor: Allogene Therapeutics
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT04416984: https://clinicaltrials.gov/study/NCT04416984

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [ALLO-647](https://onco.cc/drugs/allo-647/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/)

---
JSON: https://onco.cc/api/v1/entities/nct04416984.json